Early KCNQ2 treatment tracked with better outcomes

A 282-person cohort linked sodium channel blockers by 1 month to earlier seizure offset; LOF KCNQ2-DEE impairment odds were lower after adjustment.

THE HOT TAKE

The timing signal is strong enough to notice. The design is not strong enough to prove that starting a sodium channel blocker within the first month improves development.

This international retrospective cohort assembled 282 people with KCNQ2 variants from 21 countries. Variant review retained 276; 233 (84%) were at least 36 months old at last follow-up, including 112 with predicted loss-of-function self-limited (familial) neonatal epilepsy, 109 with loss-of-function developmental and epileptic encephalopathy (LOF-DEE), and nine with gain-of-function variants. Three others were unclassifiable. The developmental timing analysis was narrower: 36 received a sodium channel blocker (SCB) within the first month, 38 started later, and 22 never received one after short exposures and incomplete records were excluded. The journal currently provides the peer-reviewed accepted manuscript; final typesetting is pending.